SWShujing Wang

Shujing Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shujing Wang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Guilu Zhu

    Department of Pathology The First Affiliated Hospital of Wannan Medical College Wuhu Anhui China

    1 shared publication
  • Qiang Wu

    Department of Pathology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China

    1 shared publication
  • Wenjun Zhang

    Department of Pathology School of Basic Medical Science, Anhui Medical University Hefei Anhui China

    1 shared publication
  • Wuqin Xu

    Department of Pathology, The First Affiliated Hospital of Wannan Medical University, Wuhu, China

    1 shared publication
  • Youjing Sheng

    Department of Pathology The First Affiliated Hospital of the University of Science and Technology of China Hefei Anhui China

    1 shared publication

Latest Publications

  • Open Access

    Tumor‐Associated Neutrophils Regulate Breast Cancer Progression Through the AQP9/STAT3 Signaling Pathway

    by Wuqin Xu, Guilu Zhu, Youjing Sheng, Wenjun Zhang, Shujing Wang, Qiang Wu

    Tumor‐associated neutrophils (TANs) contribute to breast cancer (BC) progression, and aquaporin 9 (AQP9) plays a critical role in tumor development. However, the interactions between TANs and AQP9 in BC are poorly understood. Bioinformatics analyses and clinical samples revealed a positive correlation between neutrophil infiltration and AQP9 expression in BC. Treating BC cells with TAN‐conditioned media significantly elevated AQP9 expression compared with neutrophil‐conditioned and control media treatments. Immunohistochemical analysis revealed higher AQP9 protein expression in BC tissues than in adjacent normal tissues, and AQP9 expression was negatively correlated with recurrence‐free survival and overall survival in patients with BC. Functional studies demonstrated that AQP9 promoted BC cell proliferation but did not affect migration or invasion. AQP9 knockdown markedly inhibited the ability of TANs to enhance BC cell proliferation, migration, and invasion. Intravenous and intratumoral injection of TANs in mice increased tumor growth rate, weight, and volume compared with controls; moreover, histological examination revealed lung metastasis in two mice and bone involvement in one mouse out of six in the TAN treatment group. AQP9 knockdown significantly reduced the tumor growth rate. In BC cells, TAN treatment elevated STAT3 phosphorylation, and this effect was amplified by AQP9 overexpression. In conclusion, TANs promote BC progression by enhancing STAT3 phosphorylation through AQP9 upregulation. AQP9 is crucial for TAN‐mediated BC progression and is a potential target for immunotherapy in patients with BC.